{"gene":"BCL2L10","run_date":"2026-04-28T17:12:38","timeline":{"discoveries":[{"year":1998,"finding":"Diva (BCL2L10 mouse ortholog) promotes apoptosis independently of its BH3 domain by directly binding Apaf-1, thereby preventing Bcl-XL from interacting with Apaf-1/caspase-9. Diva did not bind cellular Bcl-2, Bcl-XL, Bcl-w, Mcl-1, or A1/Bfl-1, but was inhibited by viral Bcl-2 (vBcl-2) encoded by KSHV.","method":"Co-immunoprecipitation, overexpression apoptosis assays, BH3 deletion mutagenesis, 293T/Ramsey/T47D cell death assays","journal":"The Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP plus mutagenesis, multiple cell lines, replicated binding specificity findings","pmids":["9829980"],"is_preprint":false},{"year":1999,"finding":"Mouse Boo (BCL2L10 ortholog) is an anti-apoptotic protein that homodimerizes and heterodimerizes with pro- and anti-apoptotic Bcl-2 family members, interacts with Apaf-1, and forms a multimeric complex with Apaf-1 and caspase-9. Pro-apoptotic Bak and Bik disrupt the Boo–Apaf-1 association. Boo binds three distinct regions of Apaf-1.","method":"Co-immunoprecipitation, yeast two-hybrid, overexpression apoptosis assays","journal":"The EMBO Journal","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP with multiple binding partners, Apaf-1 domain mapping, functional disruption assays","pmids":["9878060"],"is_preprint":false},{"year":2001,"finding":"Human BCL2L10 (Bcl2-L-10) blocks the mitochondrial apoptosis pathway (cytochrome c release, caspase-3 activation, mitochondrial membrane potential collapse) induced by IL-3 withdrawal and Bax overexpression, but cannot block TNFα-induced (death receptor) apoptosis. Both the BH4 domain and the transmembrane domain are required for anti-apoptotic function.","method":"Transient transfection, flow cytometry for apoptosis and ΔΨm, caspase-3 activation assay, domain deletion mutants","journal":"Human Molecular Genetics","confidence":"High","confidence_rationale":"Tier 2 — domain mutagenesis combined with multiple functional readouts in defined pathway contexts","pmids":["11689480"],"is_preprint":false},{"year":2001,"finding":"Bcl-B (human BCL2L10) selectively binds Bax but not Bak, suppresses Bax-induced but not Bak-induced apoptosis, and requires its C-terminal transmembrane domain for association with intracellular organelles and full anti-apoptotic function. It also binds Bcl-2 and Bcl-XL.","method":"Co-immunoprecipitation, GST pulldown, transient transfection apoptosis assays, TM-deletion mutants","journal":"The Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple binding assays plus functional mutagenesis, strong mechanistic correlation","pmids":["11278245"],"is_preprint":false},{"year":2001,"finding":"Human Boo/Diva (BCL2L10) promotes cell death in HeLa and 293 cells; GFP-tagged Boo/Diva translocates from a non-mitochondrial localization to mitochondria during vincristine-induced apoptosis. Bcl-XL interacts with Boo but cannot protect cells from Boo/Diva-induced death.","method":"GFP live-cell imaging, co-immunoprecipitation, transient transfection cell death assays","journal":"Biochimica et Biophysica Acta","confidence":"Medium","confidence_rationale":"Tier 2 — direct localization experiment with functional consequence, single lab","pmids":["11566354"],"is_preprint":false},{"year":2002,"finding":"Genetic inactivation of Diva (BCL2L10) in mice shows that Diva is dispensable for normal ovarian development, fertility, and genotoxic stress-induced apoptosis, indicating functional redundancy with other Bcl-2 family members in vivo.","method":"Gene targeting (knockout mouse), histological analysis, apoptosis assays after genotoxic stress","journal":"Molecular and Cellular Biology","confidence":"High","confidence_rationale":"Tier 2 — clean genetic knockout with rigorous phenotypic analysis","pmids":["12215543"],"is_preprint":false},{"year":2003,"finding":"The differential binding specificity of Bcl-B (BCL2L10) for Bax (but not Bak) is determined by the BH3 domain of Bax: Bcl-B binds chimeric Bak containing Bax's BH3 domain, and Bcl-B BH3-pocket mutants (L86A, R96Q) lose Bax-binding and fail to suppress Bax-induced apoptosis, demonstrating tight structure–function correlation.","method":"BH3 chimeric mutants, alanine-scanning mutagenesis, structure-based BH3-pocket mutagenesis, co-immunoprecipitation, cell death assays","journal":"The Biochemical Journal","confidence":"High","confidence_rationale":"Tier 1 — structure-based mutagenesis with reconstitution of binding and functional apoptosis suppression","pmids":["12921534"],"is_preprint":false},{"year":2007,"finding":"Orphan nuclear receptor Nur77/TR3 binds BCL-B (BCL2L10) with the highest affinity among anti-apoptotic Bcl-2 family members and converts its phenotype from anti-apoptotic to pro-apoptotic. Endogenous BCL-B and Nur77 associate in RPMI 8226 myeloma cells, and BCL-B knockdown abolishes Nur77-induced apoptosis.","method":"Co-immunoprecipitation, siRNA knockdown, overexpression cell death assays, fluorescence polarization binding assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — reciprocal endogenous Co-IP, siRNA epistasis, multiple orthogonal methods","pmids":["17227826"],"is_preprint":false},{"year":2007,"finding":"NM23-H2 interacts with Diva (BCL2L10 mouse ortholog) in a transmembrane domain-dependent manner and down-regulates Diva protein levels; NM23-H2 knockdown restores Diva expression and increases Diva-mediated apoptotic activity.","method":"Yeast two-hybrid, co-immunoprecipitation, siRNA knockdown, overexpression apoptosis assays","journal":"Biochemical and Biophysical Research Communications","confidence":"Medium","confidence_rationale":"Tier 3 — single lab, Co-IP plus RNAi functional validation","pmids":["17532299"],"is_preprint":false},{"year":2008,"finding":"BCL-B (BCL2L10) shows strong preference for binding and suppressing Bax over Bak, as assessed by co-immunoprecipitation, GST pulldown, and fluorescence polarization with BH3 peptides. Mcl-1 shows the reciprocal preference for Bak, distinguishing these two anti-apoptotic proteins from Bcl-2, Bcl-XL, Bcl-w, and Bfl-1.","method":"Co-immunoprecipitation, GST pulldown, fluorescence polarization with synthetic BH3 peptides, overexpression apoptosis assays","journal":"The Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — three independent protein interaction methods plus functional apoptosis suppression assays","pmids":["18178565"],"is_preprint":false},{"year":2009,"finding":"BCL2L10 is the predominant maternally loaded Bcl-2 family transcript in oocytes and early embryos, associates with TCTP and mitochondria with stage-specific redistribution along the pericortical ooplasm, co-localizes with BAX in dying oocytes, and its neutralization accelerates oocyte death.","method":"mRNA expression profiling, immunofluorescence, co-localization imaging, antibody neutralization, fractionation","journal":"Journal of Molecular Medicine","confidence":"Medium","confidence_rationale":"Tier 2-3 — direct localization plus functional consequence via neutralization, single lab","pmids":["19551325"],"is_preprint":false},{"year":2009,"finding":"BCL2L10 knockdown by siRNA in mouse germinal vesicle oocytes causes metaphase I arrest with spindle and chromosome abnormalities, impairs maturation-promoting factor (MPF) activity, but does not affect MAPK activity, indicating a specific role for BCL2L10 in the MI-to-MII oocyte transition.","method":"Microinjection of dsRNA, real-time PCR, Western blot, immunofluorescence, MPF/MAPK activity assays","journal":"Biology of Reproduction","confidence":"High","confidence_rationale":"Tier 2 — clean RNAi knockdown with specific cellular phenotype and pathway dissection","pmids":["19439730"],"is_preprint":false},{"year":2009,"finding":"HIP1R directly interacts with BCL2L10 (human Diva/BCL-B) in a manner requiring the ANTH and THATCH domains of HIP1R; HIP1R overexpression induces BAK-dependent (but BAX-independent) mitochondrial apoptosis and augments BCL2L10–caspase-9 interaction.","method":"Yeast two-hybrid, co-immunoprecipitation, Far-Western analysis, domain deletion mutants, mitochondrial membrane potential assay, caspase-9 activation","journal":"Cellular Physiology and Biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 — direct binding confirmed by Far-Western plus domain mapping and functional epistasis","pmids":["19255499"],"is_preprint":false},{"year":2010,"finding":"BCL2L10 interacts with the BH3 domain of BECN1 (Beclin 1) and suppresses autophagy induced by multiple stimuli; BCL2L10 knockdown triggers BECN1/LC3/ATG5-dependent autophagic cell death, establishing BCL2L10 as a negative regulator of autophagy.","method":"Co-immunoprecipitation, overexpression and siRNA knockdown, autophagy flux assays (LC3), flow cytometry, ATG5/BECN1 knockdown epistasis","journal":"Autophagy","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP, multiple autophagy readouts, genetic epistasis with autophagic machinery components","pmids":["22498477"],"is_preprint":false},{"year":2010,"finding":"BCL2L10 overexpression in gastric cancer cells induces apoptosis via the mitochondrial pathway and suppresses tumor growth; BCL2L10 siRNA activates PI3K-Akt signaling to promote proliferation, indicating context-dependent dual roles in gastric cancer cells.","method":"Flow cytometry, fluorescence staining, murine xenograft, Western blot, PI3K pathway inhibitors, siRNA","journal":"The Journal of Pathology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple functional readouts in vitro and in vivo with pathway inhibitor confirmation","pmids":["21171085"],"is_preprint":false},{"year":2010,"finding":"Diva (BCL2L10 mouse ortholog) interacts with Harakiri (HRK, a BH3-only protein) via a surface equivalent to the canonical BH3-binding groove of anti-apoptotic Bcl-2 proteins, as mapped by NMR spectroscopy and molecular docking.","method":"ELISA, NMR spectroscopy, molecular docking, circular dichroism","journal":"PLoS One","confidence":"High","confidence_rationale":"Tier 1 — NMR-based structural mapping combined with binding affinity measurements","pmids":["21209886"],"is_preprint":false},{"year":2011,"finding":"BCL2L10 contains two divergent indel regions: an N-terminal extension and a loop between predicted α5-α6 helices. The α5-α6 interhelical region in human BCL2L10 has acquired negatively charged residues consistent with a calcium-binding motif; deletion of the N-terminal extension had no functional impact, while mutations in the α5-α6 loop affected protein behavior.","method":"Phylogenetic analysis, truncation and site-directed mutagenesis, biochemical assays, cell biological functional assays","journal":"Molecular Biology and Evolution","confidence":"Medium","confidence_rationale":"Tier 2 — mutagenesis with functional validation, single lab","pmids":["21705382"],"is_preprint":false},{"year":2012,"finding":"BCL2L10 (BCLb) is stabilized by Ubiquilin1 (UBQLN1) at the post-translational level; Ubqln1 promotes monoubiquitination of BCLb on multiple lysine residues and relocalizes it to the cytosol. In the absence of Ubqln1 interaction, BCLb protein is rapidly degraded after protein synthesis inhibition.","method":"Immunoaffinity purification, mass spectrometry, cycloheximide chase, co-immunoprecipitation, protein stability assays","journal":"Proceedings of the National Academy of Sciences USA","confidence":"High","confidence_rationale":"Tier 2 — MS-identified interaction, multiple biochemical validations of stability mechanism","pmids":["22233804"],"is_preprint":false},{"year":2012,"finding":"BCL-B (BCL2L10) is polyubiquitinated via K48-linked chains at lysine K128 (and potentially K119/K120) within the loop between BH1 and BH2 domains, targeting it for proteasomal degradation. A lysineless BCL-B mutant has fivefold higher protein expression and enhanced anti-apoptotic activity.","method":"Mutagenesis, mass spectrometry, linkage-specific polyubiquitin antibodies, proteasome inhibitor assays, Western blot","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 — mass spectrometry confirmed ubiquitination site, mutagenesis functional validation, replicated by independent Beverly 2012 study","pmids":["23563182"],"is_preprint":false},{"year":2012,"finding":"BCL-B (BCL2L10) has high-affinity interactions restricted to BH3-only proteins Bim and Bik only (not Bad, Bik alone broadly, PUMA, NOXA, tBid, HRK); crystal structure of BCL-B:Bim complex at 1.9 Å resolution revealed an unstructured loop insertion between helices α5 and α6 distinguishing BCL-B from other Bcl-2 family members.","method":"Crystal structure (1.9 Å), fluorescence polarization binding assays, cell-based apoptosis assays","journal":"Cell Death & Disease","confidence":"High","confidence_rationale":"Tier 1 — high-resolution crystal structure with functional validation by multiple biophysical and cell-based methods","pmids":["23235460"],"is_preprint":false},{"year":2012,"finding":"BCL-B (BCL2L10) is not targeted by BH3-mimetic ABT-737 (which targets Bcl-2, Bcl-xL, Bcl-w); BCL-B-mediated apoptosis resistance is specifically overcome by BH3-only protein Noxa but not by Bim, PUMA, or truncated Bid, as demonstrated in human T-leukemic cells with inducible expression.","method":"Inducible expression, apoptosis assays, ABT-737 drug treatment, BH3-only protein knockin/knockdown","journal":"Cell Death & Disease","confidence":"Medium","confidence_rationale":"Tier 2 — inducible expression system, multiple BH3-only proteins tested, single lab","pmids":["22875003"],"is_preprint":false},{"year":2013,"finding":"BCL2L10 knockdown sensitizes AZA-resistant myeloid cells (SKM1-R) to azacitidine-induced cell death, linking elevated BCL2L10 expression to drug resistance in myeloid cells.","method":"siRNA knockdown, cell viability assays, flow cytometry","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 — functional RNAi knockdown with specific drug-resistance phenotype, single lab","pmids":["22577154"],"is_preprint":false},{"year":2016,"finding":"IRBIT interacts with BCL2L10 and they additively inhibit IP3R in physiological conditions. Upon apoptotic stress, IRBIT is dephosphorylated and becomes an inhibitor of BCL2L10. IRBIT and BCL2L10 associate in mitochondria-associated membranes (MAMs), and IRBIT promotes ER–mitochondria contact, facilitating massive Ca2+ transfer and apoptosis.","method":"Co-immunoprecipitation, IP3R binding assays, mitochondria-associated membrane fractionation, Ca2+ imaging, apoptosis assays, phosphorylation analysis","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods including fractionation, functional Ca2+ assays, and phosphorylation-dependent mechanistic epistasis","pmids":["27995898"],"is_preprint":false},{"year":2018,"finding":"BCL2L10 (Nrh) localizes to the endoplasmic reticulum and inhibits IP3R-mediated ER-Ca2+ release through BH4 domain-dependent interaction with the ligand-binding domain of IP3R type 1/3; disruption of Nrh/IP3R complexes by BH4 mimetic peptides inhibits breast cancer cell growth in vitro and in vivo.","method":"Co-immunoprecipitation, Ca2+ release assays, subcellular fractionation, domain mutagenesis, BH4 peptide competition, xenograft mouse model","journal":"Cancer Research","confidence":"High","confidence_rationale":"Tier 1-2 — BH4 domain mutagenesis, direct IP3R binding assays, peptide disruption with in vivo validation","pmids":["29330143"],"is_preprint":false},{"year":2019,"finding":"BCL-B (BCL2L10) suppresses mitophagy in hepatic stellate cells by directly binding phosphorylated Parkin (a key mitophagy regulator) and inhibiting its phosphorylation; BCL-B knockdown increases both mitophagy and apoptosis in HSCs during hepatic fibrosis regression.","method":"Co-immunoprecipitation, Western blot for phospho-Parkin, BCL-B knockdown and overexpression, mitophagy assays, in vivo mouse fibrosis model","journal":"Experimental & Molecular Medicine","confidence":"Medium","confidence_rationale":"Tier 2 — direct binding confirmed by Co-IP, functional mitophagy assays, in vivo validation, single lab","pmids":["30635551"],"is_preprint":false},{"year":2019,"finding":"BCL2L10 inhibits autophagy in hepatoma cells by binding Beclin 1 (BECN1), which reduces the interaction between Beclin 1 and PI3KC3, thereby downregulating PI3K/AKT-dependent autophagy.","method":"Co-immunoprecipitation, ELISA, immunofluorescence co-localization, autophagic flux assay (LC3B-II/P62), pathway inhibition","journal":"Aging","confidence":"Medium","confidence_rationale":"Tier 2 — multiple binding assays and functional autophagy readouts, PI3K pathway confirmation, single lab","pmids":["30696802"],"is_preprint":false},{"year":2020,"finding":"BCL2L10 expression in melanoma is driven by STAT3-mediated transcription; functional STAT3-responsive elements in the BCL2L10 promoter were identified by reporter assays, site-directed mutagenesis, and ChIP analysis. BCL2L10 confers resistance to cisplatin and ABT-737, and its inhibition sensitizes melanoma cells to these agents.","method":"Reporter assays, site-directed mutagenesis, ChIP, siRNA knockdown, drug resistance assays, BRAF inhibitor combination","journal":"Cancers","confidence":"Medium","confidence_rationale":"Tier 2 — promoter mutagenesis plus ChIP, functional drug resistance phenotype, single lab","pmids":["33396645"],"is_preprint":false},{"year":2021,"finding":"UBQLN4 interacts with and stabilizes BCL2L10 (and BCL2A1) in mesothelioma cells; UBQLN4 is identified as an ATM kinase substrate, and the UBQLN4–BCL2L10 interaction prevents mesothelioma cell apoptosis in response to DNA damage.","method":"Genetic screening, co-immunoprecipitation, ATM substrate identification, cell death assays upon DNA damage","journal":"Molecular Oncology","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP binding confirmed, ATM substrate identification, functional apoptosis assay, single lab","pmids":["34245648"],"is_preprint":false}],"current_model":"BCL2L10 (also known as Bcl-B, Diva, Boo, Nrh) is an anti-apoptotic Bcl-2 family member that blocks the mitochondrial apoptosis pathway via BH4 domain-dependent inhibition of IP3R-mediated Ca2+ release at the ER (and in MAMs), selective binding and neutralization of pro-apoptotic Bax (but not Bak) through a restricted BH3-binding groove, inhibition of Beclin 1-dependent autophagy, and suppression of Parkin-mediated mitophagy; its protein stability is regulated by K48-linked polyubiquitination at K128 (targeting it for proteasomal degradation) which is antagonized by Ubiquilin1/UBQLN4, its anti-apoptotic phenotype can be converted to pro-apoptotic by Nur77/TR3 binding, and its expression is transcriptionally driven by STAT3."},"narrative":{"teleology":[{"year":1998,"claim":"The initial identification of Diva/BCL2L10 as a Bcl-2 family member that binds Apaf-1 and promotes apoptosis established that this gene encoded an unexpected direct modulator of the apoptosome scaffold, distinct from typical pro- or anti-apoptotic members.","evidence":"Co-IP and overexpression apoptosis assays with BH3 deletion mutants in 293T and other cell lines","pmids":["9829980"],"confidence":"High","gaps":["Pro-apoptotic function via Apaf-1 binding was later contradicted by anti-apoptotic data in human systems","Binding specificity for Apaf-1 versus Bcl-2 family members not reconciled across species"]},{"year":1999,"claim":"Demonstration that mouse Boo/BCL2L10 forms multimeric complexes with Apaf-1 and caspase-9 that are disrupted by BH3-only proteins Bak and Bik resolved its role as an anti-apoptotic guardian of the apoptosome complex.","evidence":"Co-IP, yeast two-hybrid, Apaf-1 domain mapping, and overexpression apoptosis assays","pmids":["9878060"],"confidence":"High","gaps":["Physiological stoichiometry of the Boo–Apaf-1–caspase-9 complex not determined","Whether Apaf-1 interaction is the primary anti-apoptotic mechanism in vivo remained unclear"]},{"year":2001,"claim":"Three independent studies established that human BCL2L10 is an anti-apoptotic protein that selectively binds Bax but not Bak, blocks the mitochondrial (but not death receptor) apoptosis pathway, and requires both BH4 and transmembrane domains for function, defining its mechanism as distinct from Bcl-2/Bcl-XL.","evidence":"Domain deletion mutagenesis, Co-IP, GST pulldown, flow cytometry for apoptosis and ΔΨm, GFP live-cell imaging in multiple cell lines","pmids":["11689480","11278245","11566354"],"confidence":"High","gaps":["Structural basis for Bax selectivity over Bak not yet determined","Translocation from non-mitochondrial sites to mitochondria observed but trigger mechanism unknown"]},{"year":2002,"claim":"Genetic knockout of Diva in mice revealed functional redundancy with other Bcl-2 family members, demonstrating that BCL2L10 is dispensable for normal ovarian development and genotoxic apoptosis in vivo.","evidence":"Gene targeting (knockout mouse), histological analysis, apoptosis assays after genotoxic stress","pmids":["12215543"],"confidence":"High","gaps":["Compensatory mechanisms not identified","Tissue-specific or stress-specific non-redundant roles not tested beyond ovary and genotoxic stress"]},{"year":2003,"claim":"Structure–function analysis of the BH3-binding groove revealed that BCL2L10's selectivity for Bax over Bak is determined by the BH3 domain of Bax itself, and specific groove residues (L86, R96) are required for both Bax binding and anti-apoptotic function.","evidence":"BH3 chimeric mutants, alanine-scanning and structure-based mutagenesis, Co-IP, cell death assays","pmids":["12921534"],"confidence":"High","gaps":["No crystal or NMR structure of BCL-B alone or with Bax at this time","Whether this selectivity operates in endogenous protein contexts not shown"]},{"year":2007,"claim":"Discovery that orphan nuclear receptor Nur77/TR3 binds BCL2L10 with highest affinity among anti-apoptotic Bcl-2 proteins and converts it to a pro-apoptotic effector revealed a novel regulatory switch that could override BCL2L10 survival function.","evidence":"Reciprocal endogenous Co-IP in myeloma cells, siRNA epistasis, fluorescence polarization binding assays","pmids":["17227826"],"confidence":"High","gaps":["Structural mechanism of phenotypic conversion not determined","Whether Nur77 exposes Bax or disrupts Apaf-1 complexes unknown"]},{"year":2009,"claim":"BCL2L10 was found to be the predominant Bcl-2 family transcript in oocytes, and its knockdown causes metaphase I arrest with impaired MPF activity, establishing a non-apoptotic role in oocyte meiotic maturation.","evidence":"dsRNA microinjection in mouse oocytes, immunofluorescence, MPF/MAPK activity assays, antibody neutralization","pmids":["19439730","19551325"],"confidence":"High","gaps":["How BCL2L10 regulates MPF activity is mechanistically undefined","Whether this function is Bax-dependent or independent not addressed"]},{"year":2010,"claim":"BCL2L10 was shown to bind the BH3 domain of Beclin 1 and suppress autophagy, with knockdown triggering Beclin 1/LC3/ATG5-dependent autophagic cell death, establishing BCL2L10 as a dual inhibitor of apoptosis and autophagy.","evidence":"Reciprocal Co-IP, autophagy flux assays, siRNA knockdown with genetic epistasis using ATG5 and BECN1","pmids":["22498477"],"confidence":"High","gaps":["Relative contributions of anti-apoptotic versus anti-autophagic functions in physiological contexts not dissected","Whether autophagy inhibition requires the same BH3 groove as Bax binding unknown"]},{"year":2012,"claim":"Crystal structure of BCL-B bound to Bim BH3 peptide at 1.9 Å revealed an unstructured loop between helices α5–α6 unique to BCL2L10, and biophysical profiling showed high-affinity binding restricted to Bim and Bik among BH3-only proteins, distinguishing it from all other anti-apoptotic family members.","evidence":"X-ray crystallography (1.9 Å), fluorescence polarization with BH3 peptide panel, cell-based apoptosis assays","pmids":["23235460"],"confidence":"High","gaps":["Structure of BCL-B bound to full-length Bax not available","Functional significance of the α5–α6 loop not fully resolved"]},{"year":2012,"claim":"Identification of K48-linked polyubiquitination at K128 as the primary signal for BCL2L10 proteasomal degradation, and stabilization by Ubiquilin1-mediated monoubiquitination, established the post-translational control circuit governing BCL2L10 protein levels.","evidence":"Mass spectrometry, linkage-specific ubiquitin antibodies, lysineless mutant with enhanced anti-apoptotic activity, cycloheximide chase, immunoaffinity purification","pmids":["23563182","22233804"],"confidence":"High","gaps":["E3 ligase responsible for K48-linked ubiquitination at K128 not identified","Whether mono- and polyubiquitination compete at the same lysines not resolved"]},{"year":2016,"claim":"The IRBIT–BCL2L10 interaction at mitochondria-associated membranes (MAMs) revealed a phosphorylation-dependent regulatory switch: under normal conditions both cooperatively inhibit IP3R Ca²⁺ release, but upon apoptotic stress, dephosphorylated IRBIT antagonizes BCL2L10 and promotes ER-to-mitochondria Ca²⁺ transfer to execute apoptosis.","evidence":"Co-IP, MAM fractionation, Ca²⁺ imaging, phosphorylation analysis, apoptosis assays","pmids":["27995898"],"confidence":"High","gaps":["Identity of the phosphatase that dephosphorylates IRBIT under stress not known","Whether this MAM mechanism operates in all cell types not tested"]},{"year":2018,"claim":"Demonstration that BCL2L10 inhibits IP3R-mediated Ca²⁺ release specifically through its BH4 domain interacting with the ligand-binding domain of IP3R1/3 at the ER, with BH4-mimetic peptides disrupting this interaction and suppressing breast cancer growth in vivo, defined a druggable ER-localized anti-apoptotic mechanism.","evidence":"Co-IP, Ca²⁺ release assays, subcellular fractionation, BH4 domain mutagenesis, BH4 peptide competition, xenograft model","pmids":["29330143"],"confidence":"High","gaps":["Structural details of BH4–IP3R interface not resolved at atomic level","Whether BH4 peptides affect other BH4-dependent interactions not assessed"]},{"year":2019,"claim":"BCL2L10 was shown to suppress Parkin-mediated mitophagy by directly binding phosphorylated Parkin and inhibiting its phosphorylation, expanding BCL2L10's protective repertoire to mitochondrial quality control in hepatic stellate cells.","evidence":"Co-IP of BCL-B with phospho-Parkin, knockdown and overexpression, mitophagy assays, in vivo mouse fibrosis model","pmids":["30635551"],"confidence":"Medium","gaps":["Mechanism by which BCL2L10 inhibits Parkin phosphorylation (PINK1 competition?) not determined","Single lab finding in hepatic stellate cells; generalizability unclear","Reciprocal validation with endogenous proteins limited"]},{"year":2020,"claim":"Identification of STAT3 as a direct transcriptional activator of BCL2L10 through functional promoter elements linked BCL2L10 upregulation to oncogenic signaling and chemotherapy resistance in melanoma.","evidence":"Promoter reporter assays, site-directed mutagenesis of STAT3 elements, ChIP, siRNA knockdown, drug resistance assays","pmids":["33396645"],"confidence":"Medium","gaps":["Whether STAT3 drives BCL2L10 in non-melanoma contexts not established","Additional transcription factors regulating BCL2L10 not characterized"]},{"year":2021,"claim":"UBQLN4 was identified as a second Ubiquilin family stabilizer of BCL2L10 and linked to ATM-dependent DNA damage signaling, connecting BCL2L10 protein stability to the DNA damage response in mesothelioma.","evidence":"Genetic screening, Co-IP, ATM substrate identification, cell death assays upon DNA damage","pmids":["34245648"],"confidence":"Medium","gaps":["Whether UBQLN1 and UBQLN4 act redundantly or in different contexts not resolved","How ATM phosphorylation of UBQLN4 modulates BCL2L10 binding not mechanistically defined"]},{"year":null,"claim":"The E3 ubiquitin ligase targeting BCL2L10 for K48-linked degradation remains unidentified, the structural basis of Nur77-mediated phenotypic conversion is unknown, and how BCL2L10 regulates MPF activity during oocyte meiosis has no mechanistic explanation.","evidence":"","pmids":[],"confidence":"High","gaps":["E3 ligase for K48-linked ubiquitination at K128 not identified","No structure of BCL2L10 with full-length Bax or Nur77","Mechanism linking BCL2L10 to MPF regulation in oocytes completely unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[2,3,6,9,13,23,24,25]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[2,4,10,22]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[22,23]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[17]}],"pathway":[{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[0,1,2,3,6,7,9,18,22,23]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[13,25]},{"term_id":"R-HSA-1852241","term_label":"Organelle biogenesis and maintenance","supporting_discovery_ids":[24]}],"complexes":[],"partners":["BAX","BECN1","APAF1","ITPR1","NR4A1","UBQLN1","UBQLN4","PRKN"],"other_free_text":[]},"mechanistic_narrative":"BCL2L10 is an anti-apoptotic Bcl-2 family member that guards against mitochondrial apoptosis, autophagy, and mitophagy through distinct molecular interactions. It selectively binds and neutralizes pro-apoptotic Bax (but not Bak) via a restricted BH3-binding groove, with specificity determined by the Bax BH3 domain and key groove residues (L86, R96), and additionally inhibits IP3R-mediated ER Ca²⁺ release through its BH4 domain at ER and mitochondria-associated membranes, thereby suppressing Ca²⁺-driven apoptotic signaling [PMID:11689480, PMID:11278245, PMID:12921534, PMID:29330143, PMID:27995898]. BCL2L10 also negatively regulates Beclin 1-dependent autophagy and Parkin-mediated mitophagy through direct binding of these effectors [PMID:22498477, PMID:30635551]. Its protein stability is controlled by K48-linked polyubiquitination at K128 targeting it for proteasomal degradation, counteracted by stabilizing interactions with Ubiquilin1 and UBQLN4, while the orphan nuclear receptor Nur77 converts BCL2L10 from anti-apoptotic to pro-apoptotic upon binding [PMID:23563182, PMID:22233804, PMID:34245648, PMID:17227826]. Transcription of BCL2L10 is driven by STAT3, and its expression confers chemotherapy resistance in melanoma and myeloid malignancies [PMID:33396645, PMID:22577154]."},"prefetch_data":{"uniprot":{"accession":"Q9HD36","full_name":"Bcl-2-like protein 10","aliases":["Anti-apoptotic protein Boo","Anti-apoptotic protein NrH","Apoptosis regulator Bcl-B"],"length_aa":204,"mass_kda":23.2,"function":"Promotes cell survival by suppressing apoptosis induced by BAX but not BAK (PubMed:11278245, PubMed:11689480). Increases binding of AHCYL1/IRBIT to ITPR1 (PubMed:27995898). Reduces ITPR1-mediated calcium release from the endoplasmic reticulum cooperatively with AHCYL1/IRBIT under normal cellular conditions (PubMed:27995898). Under apoptotic stress conditions, dissociates from ITPR1 and is displaced from mitochondria-associated endoplasmic reticulum membranes, leading to increased Ca(2+) transfer to mitochondria which promotes apoptosis (PubMed:27995898). Required for the correct formation of the microtubule organizing center during oocyte cell division, potentially via regulation of protein abundance and localization of other microtubule organizing center components such as AURKA and TPX2 (By similarity)","subcellular_location":"Mitochondrion; Nucleus membrane; Endoplasmic reticulum; Cytoplasm, cytoskeleton, spindle","url":"https://www.uniprot.org/uniprotkb/Q9HD36/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/BCL2L10","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/BCL2L10","total_profiled":1310},"omim":[{"mim_id":"606910","title":"BCL2-LIKE 10; BCL2L10","url":"https://www.omim.org/entry/606910"},{"mim_id":"254500","title":"MYELOMA, MULTIPLE","url":"https://www.omim.org/entry/254500"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"liver","ntpm":9.2},{"tissue":"skin 1","ntpm":6.5}],"url":"https://www.proteinatlas.org/search/BCL2L10"},"hgnc":{"alias_symbol":["Diva","Boo","BCL-B"],"prev_symbol":[]},"alphafold":{"accession":"Q9HD36","domains":[{"cath_id":"1.10.437.10","chopping":"13-173","consensus_level":"high","plddt":90.487,"start":13,"end":173},{"cath_id":"1.20.5","chopping":"176-204","consensus_level":"medium","plddt":79.3924,"start":176,"end":204}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9HD36","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9HD36-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9HD36-F1-predicted_aligned_error_v6.png","plddt_mean":85.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BCL2L10","jax_strain_url":"https://www.jax.org/strain/search?query=BCL2L10"},"sequence":{"accession":"Q9HD36","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9HD36.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9HD36/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9HD36"}},"corpus_meta":[{"pmid":"12745380","id":"PMC_12745380","title":"Development of a DIVA (Differentiating Infected from Vaccinated Animals) strategy using a vaccine containing a heterologous neuraminidase for the control of avian influenza.","date":"2003","source":"Avian pathology : journal of the W.V.P.A","url":"https://pubmed.ncbi.nlm.nih.gov/12745380","citation_count":157,"is_preprint":false},{"pmid":"10486928","id":"PMC_10486928","title":"Diva vaccines that reduce virus transmission.","date":"1999","source":"Journal of biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/10486928","citation_count":153,"is_preprint":false},{"pmid":"9829980","id":"PMC_9829980","title":"Diva, a Bcl-2 homologue that binds directly to Apaf-1 and induces BH3-independent cell death.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9829980","citation_count":144,"is_preprint":false},{"pmid":"9878060","id":"PMC_9878060","title":"Boo, a novel negative regulator of cell death, interacts with Apaf-1.","date":"1999","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/9878060","citation_count":143,"is_preprint":false},{"pmid":"18178565","id":"PMC_18178565","title":"Differential regulation of Bax and Bak by anti-apoptotic Bcl-2 family proteins Bcl-B and Mcl-1.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18178565","citation_count":113,"is_preprint":false},{"pmid":"11278245","id":"PMC_11278245","title":"Bcl-B, a novel Bcl-2 family member that differentially binds and regulates Bax and Bak.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11278245","citation_count":104,"is_preprint":false},{"pmid":"15297071","id":"PMC_15297071","title":"Generation of reassortant influenza vaccines by reverse genetics that allows utilization of a DIVA (Differentiating Infected from Vaccinated Animals) strategy for the control of avian influenza.","date":"2004","source":"Vaccine","url":"https://pubmed.ncbi.nlm.nih.gov/15297071","citation_count":89,"is_preprint":false},{"pmid":"16257543","id":"PMC_16257543","title":"Overview of avian influenza DIVA test strategies.","date":"2005","source":"Biologicals : journal of the International Association of Biological Standardization","url":"https://pubmed.ncbi.nlm.nih.gov/16257543","citation_count":78,"is_preprint":false},{"pmid":"22875003","id":"PMC_22875003","title":"Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.","date":"2012","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/22875003","citation_count":74,"is_preprint":false},{"pmid":"29782836","id":"PMC_29782836","title":"Dancing with the Diva: Hsp90-Client Interactions.","date":"2018","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/29782836","citation_count":73,"is_preprint":false},{"pmid":"22577154","id":"PMC_22577154","title":"BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients.","date":"2012","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/22577154","citation_count":71,"is_preprint":false},{"pmid":"17227826","id":"PMC_17227826","title":"Nur77 converts phenotype of Bcl-B, an antiapoptotic protein expressed in plasma cells and myeloma.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17227826","citation_count":71,"is_preprint":false},{"pmid":"27995898","id":"PMC_27995898","title":"IRBIT controls apoptosis by interacting with the Bcl-2 homolog, Bcl2l10, and by promoting ER-mitochondria contact.","date":"2016","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/27995898","citation_count":62,"is_preprint":false},{"pmid":"22233804","id":"PMC_22233804","title":"Ubiquitination, localization, and stability of an anti-apoptotic BCL2-like protein, BCL2L10/BCLb, are regulated by Ubiquilin1.","date":"2012","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/22233804","citation_count":62,"is_preprint":false},{"pmid":"23235460","id":"PMC_23235460","title":"The restricted binding repertoire of Bcl-B leaves Bim as the universal BH3-only prosurvival Bcl-2 protein antagonist.","date":"2012","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/23235460","citation_count":61,"is_preprint":false},{"pmid":"11689480","id":"PMC_11689480","title":"Bcl2-L-10, a novel anti-apoptotic member of the Bcl-2 family, blocks apoptosis in the mitochondria death pathway but not in the death receptor pathway.","date":"2001","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11689480","citation_count":59,"is_preprint":false},{"pmid":"34668772","id":"PMC_34668772","title":"Deletion of E184L, a Putative DIVA Target from the Pandemic Strain of African Swine Fever Virus, Produces a Reduction in Virulence and Protection against Virulent Challenge.","date":"2021","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/34668772","citation_count":52,"is_preprint":false},{"pmid":"30635551","id":"PMC_30635551","title":"The role of the apoptosis-related protein BCL-B in the regulation of mitophagy in hepatic stellate cells during the regression of liver fibrosis.","date":"2019","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30635551","citation_count":51,"is_preprint":false},{"pmid":"18483366","id":"PMC_18483366","title":"Bcl-B expression in human epithelial and nonepithelial malignancies.","date":"2008","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/18483366","citation_count":50,"is_preprint":false},{"pmid":"22498477","id":"PMC_22498477","title":"The anti-apoptotic Bcl-B protein inhibits BECN1-dependent autophagic cell death.","date":"2012","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/22498477","citation_count":44,"is_preprint":false},{"pmid":"24568545","id":"PMC_24568545","title":"Recombinant adenovirus expressing the haemagglutinin of Peste des petits ruminants virus (PPRV) protects goats against challenge with pathogenic virus; a DIVA vaccine for PPR.","date":"2014","source":"Veterinary research","url":"https://pubmed.ncbi.nlm.nih.gov/24568545","citation_count":42,"is_preprint":false},{"pmid":"19551325","id":"PMC_19551325","title":"Oocytes and early embryos selectively express the survival factor BCL2L10.","date":"2009","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/19551325","citation_count":37,"is_preprint":false},{"pmid":"29330143","id":"PMC_29330143","title":"Breast Cancer Targeting through Inhibition of the Endoplasmic Reticulum-Based Apoptosis Regulator Nrh/BCL2L10.","date":"2018","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/29330143","citation_count":36,"is_preprint":false},{"pmid":"32664700","id":"PMC_32664700","title":"Aujeszky's Disease and the Development of the Marker/DIVA Vaccination Concept.","date":"2020","source":"Pathogens (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/32664700","citation_count":36,"is_preprint":false},{"pmid":"17532299","id":"PMC_17532299","title":"NM23-H2 involves in negative regulation of Diva and Bcl2L10 in apoptosis signaling.","date":"2007","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/17532299","citation_count":35,"is_preprint":false},{"pmid":"17027123","id":"PMC_17027123","title":"Development of a DIVA subunit vaccine against Actinobacillus pleuropneumoniae infection.","date":"2006","source":"Vaccine","url":"https://pubmed.ncbi.nlm.nih.gov/17027123","citation_count":35,"is_preprint":false},{"pmid":"18538899","id":"PMC_18538899","title":"Development of a porcine reproductive and respiratory syndrome virus differentiable (DIVA) strain through deletion of specific immunodominant epitopes.","date":"2008","source":"Vaccine","url":"https://pubmed.ncbi.nlm.nih.gov/18538899","citation_count":34,"is_preprint":false},{"pmid":"21171085","id":"PMC_21171085","title":"BCL2L10 protein regulates apoptosis/proliferation through differential pathways in gastric cancer cells.","date":"2010","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21171085","citation_count":33,"is_preprint":false},{"pmid":"11566354","id":"PMC_11566354","title":"Characterization of NR13-related human cell death regulator, Boo/Diva, in normal and cancer tissues.","date":"2001","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/11566354","citation_count":32,"is_preprint":false},{"pmid":"12921534","id":"PMC_12921534","title":"Characterization of the anti-apoptotic mechanism of Bcl-B.","date":"2003","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/12921534","citation_count":31,"is_preprint":false},{"pmid":"19439730","id":"PMC_19439730","title":"Role of Bcl2-like 10 (Bcl2l10) in Regulating Mouse Oocyte Maturation.","date":"2009","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/19439730","citation_count":30,"is_preprint":false},{"pmid":"35862688","id":"PMC_35862688","title":"Evaluation of the Deletion of MGF110-5L-6L on Swine Virulence from the Pandemic Strain of African Swine Fever Virus and Use as a DIVA Marker in Vaccine Candidate ASFV-G-ΔI177L.","date":"2022","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/35862688","citation_count":29,"is_preprint":false},{"pmid":"21444705","id":"PMC_21444705","title":"Raltegravir concentrations in the genital tract of HIV-1-infected women treated with a raltegravir-containing regimen (DIVA 01 study).","date":"2011","source":"Antimicrobial agents and chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/21444705","citation_count":29,"is_preprint":false},{"pmid":"16595309","id":"PMC_16595309","title":"Development and validation of an anti-N3 indirect immunofluorescent antibody test to be used as a companion diagnostic test in the framework of a \"DIVA\" vaccination strategy for avian influenza infections in poultry.","date":"2006","source":"Avian pathology : journal of the W.V.P.A","url":"https://pubmed.ncbi.nlm.nih.gov/16595309","citation_count":29,"is_preprint":false},{"pmid":"25869887","id":"PMC_25869887","title":"Intermediate rough Brucella abortus S19Δper mutant is DIVA enable, safe to pregnant guinea pigs and confers protection to mice.","date":"2015","source":"Vaccine","url":"https://pubmed.ncbi.nlm.nih.gov/25869887","citation_count":28,"is_preprint":false},{"pmid":"20919753","id":"PMC_20919753","title":"Homology modeling and docking studies of human Bcl-2L10 protein.","date":"2010","source":"Journal of biomolecular structure & dynamics","url":"https://pubmed.ncbi.nlm.nih.gov/20919753","citation_count":27,"is_preprint":false},{"pmid":"23561290","id":"PMC_23561290","title":"Virus-like particles: promising platforms with characteristics of DIVA for veterinary vaccine design.","date":"2013","source":"Comparative immunology, microbiology and infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/23561290","citation_count":27,"is_preprint":false},{"pmid":"12215543","id":"PMC_12215543","title":"Murine ovarian development is not affected by inactivation of the bcl-2 family member diva.","date":"2002","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12215543","citation_count":27,"is_preprint":false},{"pmid":"19233575","id":"PMC_19233575","title":"A DIVA system based on the detection of antibodies to non-structural protein 3 (NS3) of bluetongue virus.","date":"2009","source":"Veterinary microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/19233575","citation_count":27,"is_preprint":false},{"pmid":"18638504","id":"PMC_18638504","title":"DIVA diagnostic of Aujeszky's disease using an insect-derived virus glycoprotein E.","date":"2008","source":"Journal of virological methods","url":"https://pubmed.ncbi.nlm.nih.gov/18638504","citation_count":27,"is_preprint":false},{"pmid":"35177041","id":"PMC_35177041","title":"Improving peripheral venous cannula insertion in children: a mixed methods study to develop the DIVA key.","date":"2022","source":"BMC health services research","url":"https://pubmed.ncbi.nlm.nih.gov/35177041","citation_count":26,"is_preprint":false},{"pmid":"25312275","id":"PMC_25312275","title":"Strong protection induced by an experimental DIVA subunit vaccine against bluetongue virus serotype 8 in cattle.","date":"2014","source":"Vaccine","url":"https://pubmed.ncbi.nlm.nih.gov/25312275","citation_count":24,"is_preprint":false},{"pmid":"26900835","id":"PMC_26900835","title":"Avian Influenza Virus and DIVA Strategies.","date":"2016","source":"Viral immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26900835","citation_count":23,"is_preprint":false},{"pmid":"34311189","id":"PMC_34311189","title":"The roles of MCP-1/CCR2 mediated macrophage recruitment and polarization in bladder outlet obstruction (BOO) induced bladder remodeling.","date":"2021","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34311189","citation_count":23,"is_preprint":false},{"pmid":"20521645","id":"PMC_20521645","title":"Differentiation of infected and vaccinated animals (DIVA) using the NS1 protein of avian influenza virus.","date":"2010","source":"Avian diseases","url":"https://pubmed.ncbi.nlm.nih.gov/20521645","citation_count":23,"is_preprint":false},{"pmid":"27455953","id":"PMC_27455953","title":"BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice.","date":"2016","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27455953","citation_count":23,"is_preprint":false},{"pmid":"25454873","id":"PMC_25454873","title":"VP2-serotyped live-attenuated bluetongue virus without NS3/NS3a expression provides serotype-specific protection and enables DIVA.","date":"2014","source":"Vaccine","url":"https://pubmed.ncbi.nlm.nih.gov/25454873","citation_count":23,"is_preprint":false},{"pmid":"19255499","id":"PMC_19255499","title":"HIP1R interacts with a member of Bcl-2 family, BCL2L10, and induces BAK-dependent cell death.","date":"2009","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/19255499","citation_count":22,"is_preprint":false},{"pmid":"20428828","id":"PMC_20428828","title":"BCL2L10 is frequently silenced by promoter hypermethylation in gastric cancer.","date":"2010","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/20428828","citation_count":22,"is_preprint":false},{"pmid":"33835201","id":"PMC_33835201","title":"Application of portable real-time recombinase-aided amplification (rt-RAA) assay in the clinical diagnosis of ASFV and prospective DIVA diagnosis.","date":"2021","source":"Applied microbiology and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/33835201","citation_count":22,"is_preprint":false},{"pmid":"22716302","id":"PMC_22716302","title":"Protective efficacy of crude virus-like particle vaccine against HPAI H5N1 in chickens and its application on DIVA strategy.","date":"2012","source":"Influenza and other respiratory viruses","url":"https://pubmed.ncbi.nlm.nih.gov/22716302","citation_count":22,"is_preprint":false},{"pmid":"14612420","id":"PMC_14612420","title":"The DIVa maturase binding site in the yeast group II intron aI2 is essential for intron homing but not for in vivo splicing.","date":"2003","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/14612420","citation_count":22,"is_preprint":false},{"pmid":"24047476","id":"PMC_24047476","title":"The BCL2L10 Leu21Arg variant and risk of therapy-related myeloid neoplasms and de novo myelodysplastic syndromes.","date":"2013","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/24047476","citation_count":21,"is_preprint":false},{"pmid":"35835806","id":"PMC_35835806","title":"Test performance data demonstrates utility of a cattle DIVA skin test reagent (DST-F) compatible with BCG vaccination.","date":"2022","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/35835806","citation_count":21,"is_preprint":false},{"pmid":"22378549","id":"PMC_22378549","title":"Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group.","date":"2012","source":"The new microbiologica","url":"https://pubmed.ncbi.nlm.nih.gov/22378549","citation_count":21,"is_preprint":false},{"pmid":"26836212","id":"PMC_26836212","title":"A DIVA vaccine for cross-protection against Salmonella.","date":"2016","source":"Vaccine","url":"https://pubmed.ncbi.nlm.nih.gov/26836212","citation_count":20,"is_preprint":false},{"pmid":"33396645","id":"PMC_33396645","title":"BCL2L10 Is Overexpressed in Melanoma Downstream of STAT3 and Promotes Cisplatin and ABT-737 Resistance.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/33396645","citation_count":19,"is_preprint":false},{"pmid":"22804620","id":"PMC_22804620","title":"RHCE*ceTI encodes partial c and partial e and is often in cis to RHD*DIVa.","date":"2012","source":"Transfusion","url":"https://pubmed.ncbi.nlm.nih.gov/22804620","citation_count":19,"is_preprint":false},{"pmid":"27626934","id":"PMC_27626934","title":"Chimeric Bivalent Virus-Like Particle Vaccine for H5N1 HPAI and ND Confers Protection against a Lethal Challenge in Chickens and Allows a Strategy of Differentiating Infected from Vaccinated Animals (DIVA).","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27626934","citation_count":19,"is_preprint":false},{"pmid":"33253485","id":"PMC_33253485","title":"Performance of the currently available DIVA real-time PCR assays in classical and recombinant lumpy skin disease viruses.","date":"2021","source":"Transboundary and emerging diseases","url":"https://pubmed.ncbi.nlm.nih.gov/33253485","citation_count":19,"is_preprint":false},{"pmid":"22108430","id":"PMC_22108430","title":"Development of a combined canine distemper virus specific RT-PCR protocol for the differentiation of infected and vaccinated animals (DIVA) and genetic characterization of the hemagglutinin gene of seven Chinese strains demonstrated in dogs.","date":"2011","source":"Journal of virological methods","url":"https://pubmed.ncbi.nlm.nih.gov/22108430","citation_count":19,"is_preprint":false},{"pmid":"27770580","id":"PMC_27770580","title":"BCL2L10 inhibits growth and metastasis of hepatocellular carcinoma both in vitro and in vivo.","date":"2016","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/27770580","citation_count":18,"is_preprint":false},{"pmid":"21507263","id":"PMC_21507263","title":"Proteomic and immunoproteomic characterization of a DIVA subunit vaccine against Actinobacillus pleuropneumoniae.","date":"2011","source":"Proteome science","url":"https://pubmed.ncbi.nlm.nih.gov/21507263","citation_count":18,"is_preprint":false},{"pmid":"35005368","id":"PMC_35005368","title":"Boo-boos as the building blocks of pain expression: An observational examination of parental responses to everyday pain in toddlers.","date":"2018","source":"Canadian journal of pain = Revue canadienne de la douleur","url":"https://pubmed.ncbi.nlm.nih.gov/35005368","citation_count":17,"is_preprint":false},{"pmid":"30519035","id":"PMC_30519035","title":"MicroRNA-18a promotes hepatocellular carcinoma proliferation, migration, and invasion by targeting Bcl2L10.","date":"2018","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/30519035","citation_count":17,"is_preprint":false},{"pmid":"30696802","id":"PMC_30696802","title":"BCL2L10/BECN1 modulates hepatoma cells autophagy by regulating PI3K/AKT signaling pathway.","date":"2019","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/30696802","citation_count":16,"is_preprint":false},{"pmid":"23563182","id":"PMC_23563182","title":"Polyubiquitination and proteasomal turnover controls the anti-apoptotic activity of Bcl-B.","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/23563182","citation_count":16,"is_preprint":false},{"pmid":"11557035","id":"PMC_11557035","title":"Diva/Boo is a negative regulator of cell death in human glioma cells.","date":"2001","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/11557035","citation_count":16,"is_preprint":false},{"pmid":"28516860","id":"PMC_28516860","title":"Salmonella DIVA vaccine reduces disease, colonization and shedding due to virulent S. Typhimurium infection in swine.","date":"2017","source":"Journal of medical microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/28516860","citation_count":16,"is_preprint":false},{"pmid":"34991038","id":"PMC_34991038","title":"Safety and protective efficacy of Salmonella Pullorum spiC and rfaH deletion rough mutant as a live attenuated DIVA vaccine candidate.","date":"2021","source":"Poultry science","url":"https://pubmed.ncbi.nlm.nih.gov/34991038","citation_count":16,"is_preprint":false},{"pmid":"31839315","id":"PMC_31839315","title":"Coastal flood risks in China through the 21st century - An application of DIVA.","date":"2019","source":"The Science of the total environment","url":"https://pubmed.ncbi.nlm.nih.gov/31839315","citation_count":16,"is_preprint":false},{"pmid":"26387435","id":"PMC_26387435","title":"Development of a competitive ELISA for NS3 antibodies as DIVA test accompanying the novel Disabled Infectious Single Animal (DISA) vaccine for Bluetongue.","date":"2015","source":"Vaccine","url":"https://pubmed.ncbi.nlm.nih.gov/26387435","citation_count":16,"is_preprint":false},{"pmid":"19686695","id":"PMC_19686695","title":"Comparative efficacy of North American and antigenically matched reverse genetics derived H5N9 DIVA marker vaccines against highly pathogenic Asian H5N1 avian influenza viruses in chickens.","date":"2009","source":"Vaccine","url":"https://pubmed.ncbi.nlm.nih.gov/19686695","citation_count":16,"is_preprint":false},{"pmid":"21209886","id":"PMC_21209886","title":"Characterization of a novel interaction between Bcl-2 members Diva and Harakiri.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21209886","citation_count":14,"is_preprint":false},{"pmid":"30549198","id":"PMC_30549198","title":"MicroRNA-101 protects bladder of BOO from hypoxia-induced fibrosis by attenuating TGF-β-smad2/3 signaling.","date":"2018","source":"IUBMB life","url":"https://pubmed.ncbi.nlm.nih.gov/30549198","citation_count":13,"is_preprint":false},{"pmid":"37899453","id":"PMC_37899453","title":"Bcl-B: an \"unknown\" protein of the Bcl-2 family.","date":"2023","source":"Biology direct","url":"https://pubmed.ncbi.nlm.nih.gov/37899453","citation_count":13,"is_preprint":false},{"pmid":"31323195","id":"PMC_31323195","title":"The potential of a DIVA-like recombinant vaccine composed by rNcSAG1 and rAtHsp81.2 against vertical transmission in a mouse model of congenital neosporosis.","date":"2019","source":"Acta tropica","url":"https://pubmed.ncbi.nlm.nih.gov/31323195","citation_count":13,"is_preprint":false},{"pmid":"19543688","id":"PMC_19543688","title":"Generation and evaluation of an H9N1 influenza vaccine derived by reverse genetics that allows utilization of a DIVA strategy for control of H9N2 avian influenza.","date":"2009","source":"Archives of virology","url":"https://pubmed.ncbi.nlm.nih.gov/19543688","citation_count":13,"is_preprint":false},{"pmid":"20381545","id":"PMC_20381545","title":"Detection of Mycoplasma mycoides subsp. mycoides SC in bronchoalveolar lavage fluids of cows based on a TaqMan real-time PCR discriminating wild type strains from an lppQ(-) mutant vaccine strain used for DIVA-strategies.","date":"2010","source":"Journal of microbiological methods","url":"https://pubmed.ncbi.nlm.nih.gov/20381545","citation_count":13,"is_preprint":false},{"pmid":"23892102","id":"PMC_23892102","title":"Characterization of a serologic marker candidate for development of a live-attenuated DIVA vaccine against porcine reproductive and respiratory syndrome virus.","date":"2013","source":"Vaccine","url":"https://pubmed.ncbi.nlm.nih.gov/23892102","citation_count":12,"is_preprint":false},{"pmid":"21907751","id":"PMC_21907751","title":"Development of DIVA (differentiation of infected from vaccinated animals) vaccines utilizing heterologous NA and NS1 protein strategies for the control of triple reassortant H3N2 influenza in turkeys.","date":"2011","source":"Vaccine","url":"https://pubmed.ncbi.nlm.nih.gov/21907751","citation_count":12,"is_preprint":false},{"pmid":"36113357","id":"PMC_36113357","title":"Prospective lipid-A altered live attenuated Salmonella Gallinarum confers protectivity, DIVA capability, safety and low endotoxicity against fowl typhoid.","date":"2022","source":"Veterinary microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/36113357","citation_count":12,"is_preprint":false},{"pmid":"21705382","id":"PMC_21705382","title":"Characterization of unique signature sequences in the divergent maternal protein Bcl2l10.","date":"2011","source":"Molecular biology and evolution","url":"https://pubmed.ncbi.nlm.nih.gov/21705382","citation_count":11,"is_preprint":false},{"pmid":"22905226","id":"PMC_22905226","title":"Diva reduces cell death in response to oxidative stress and cytotoxicity.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22905226","citation_count":11,"is_preprint":false},{"pmid":"34585985","id":"PMC_34585985","title":"Development of an Inactivated H7N9 Subtype Avian Influenza Serological DIVA Vaccine Using the Chimeric HA Epitope Approach.","date":"2021","source":"Microbiology spectrum","url":"https://pubmed.ncbi.nlm.nih.gov/34585985","citation_count":11,"is_preprint":false},{"pmid":"32354145","id":"PMC_32354145","title":"A Novel Recombinant Newcastle Disease Virus Vectored DIVA Vaccine against Peste des Petits Ruminants in Goats.","date":"2020","source":"Vaccines","url":"https://pubmed.ncbi.nlm.nih.gov/32354145","citation_count":11,"is_preprint":false},{"pmid":"34696258","id":"PMC_34696258","title":"Pentavalent Disabled Infectious Single Animal (DISA)/DIVA Vaccine Provides Protection in Sheep and Cattle against Different Serotypes of Bluetongue Virus.","date":"2021","source":"Vaccines","url":"https://pubmed.ncbi.nlm.nih.gov/34696258","citation_count":11,"is_preprint":false},{"pmid":"19446190","id":"PMC_19446190","title":"Novel use of a N2-specific enzyme-linked immunosorbent assay for differentiation of infected from vaccinated animals (DIVA)-based identification of avian influenza.","date":"2009","source":"Vaccine","url":"https://pubmed.ncbi.nlm.nih.gov/19446190","citation_count":11,"is_preprint":false},{"pmid":"24629779","id":"PMC_24629779","title":"DIVA vaccine properties of the live chimeric pestivirus strain CP7_E2gif.","date":"2014","source":"Veterinary microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/24629779","citation_count":11,"is_preprint":false},{"pmid":"34245648","id":"PMC_34245648","title":"UBQLN4 is an ATM substrate that stabilizes the anti-apoptotic proteins BCL2A1 and BCL2L10 in mesothelioma.","date":"2021","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34245648","citation_count":10,"is_preprint":false},{"pmid":"18626112","id":"PMC_18626112","title":"A TR3/Nur77 peptide-based high-throughput fluorescence polarization screen for small molecule Bcl-B inhibitors.","date":"2008","source":"Journal of biomolecular screening","url":"https://pubmed.ncbi.nlm.nih.gov/18626112","citation_count":10,"is_preprint":false},{"pmid":"22526321","id":"PMC_22526321","title":"Etravirine concentrations in the cervicovaginal compartment in HIV-1-infected women receiving etravirine-containing antiretroviral therapy: DIVA 02 study.","date":"2012","source":"Antimicrobial agents and chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/22526321","citation_count":10,"is_preprint":false},{"pmid":"24304918","id":"PMC_24304918","title":"Effect of a DIVA vaccine with and without in-feed use of coated calcium-butyrate on transmission of Salmonella Typhimurium in pigs.","date":"2013","source":"BMC veterinary research","url":"https://pubmed.ncbi.nlm.nih.gov/24304918","citation_count":10,"is_preprint":false},{"pmid":"20483193","id":"PMC_20483193","title":"Population-based analysis of Actinobacillus pleuropneumoniae ApxIVA for use as a DIVA antigen.","date":"2010","source":"Vaccine","url":"https://pubmed.ncbi.nlm.nih.gov/20483193","citation_count":10,"is_preprint":false},{"pmid":"34067226","id":"PMC_34067226","title":"The Bluetongue Disabled Infectious Single Animal (DISA) Vaccine Platform Based on Deletion NS3/NS3a Protein Is Safe and Protective in Cattle and Enables DIVA.","date":"2021","source":"Viruses","url":"https://pubmed.ncbi.nlm.nih.gov/34067226","citation_count":10,"is_preprint":false},{"pmid":"31894274","id":"PMC_31894274","title":"Bcl2l10 mediates the proliferation, invasion and migration of ovarian cancer cells.","date":"2019","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31894274","citation_count":9,"is_preprint":false},{"pmid":"34232473","id":"PMC_34232473","title":"BOO induces fibrosis and EMT in urothelial cells which can be recapitulated in vitro through elevated storage and voiding pressure cycles.","date":"2021","source":"International urology and nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/34232473","citation_count":9,"is_preprint":false},{"pmid":"30518911","id":"PMC_30518911","title":"Differential viral accessibility (DIVA) identifies alterations in chromatin architecture through large-scale mapping of lentiviral integration sites.","date":"2019","source":"Nature protocols","url":"https://pubmed.ncbi.nlm.nih.gov/30518911","citation_count":9,"is_preprint":false},{"pmid":"29371108","id":"PMC_29371108","title":"The importance of area scaling with FACS DIVA software.","date":"2018","source":"Methods (San Diego, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/29371108","citation_count":9,"is_preprint":false},{"pmid":"35568244","id":"PMC_35568244","title":"Assessing an O-antigen deficient, live attenuated Salmonella Gallinarium strain that is DIVA compatible, environmentally safe, and protects chickens against fowl typhoid.","date":"2022","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35568244","citation_count":9,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50351,"output_tokens":6566,"usd":0.124771},"stage2":{"model":"claude-opus-4-6","input_tokens":10252,"output_tokens":3996,"usd":0.22674},"total_usd":0.351511,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"Diva (BCL2L10 mouse ortholog) promotes apoptosis independently of its BH3 domain by directly binding Apaf-1, thereby preventing Bcl-XL from interacting with Apaf-1/caspase-9. Diva did not bind cellular Bcl-2, Bcl-XL, Bcl-w, Mcl-1, or A1/Bfl-1, but was inhibited by viral Bcl-2 (vBcl-2) encoded by KSHV.\",\n      \"method\": \"Co-immunoprecipitation, overexpression apoptosis assays, BH3 deletion mutagenesis, 293T/Ramsey/T47D cell death assays\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP plus mutagenesis, multiple cell lines, replicated binding specificity findings\",\n      \"pmids\": [\"9829980\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Mouse Boo (BCL2L10 ortholog) is an anti-apoptotic protein that homodimerizes and heterodimerizes with pro- and anti-apoptotic Bcl-2 family members, interacts with Apaf-1, and forms a multimeric complex with Apaf-1 and caspase-9. Pro-apoptotic Bak and Bik disrupt the Boo–Apaf-1 association. Boo binds three distinct regions of Apaf-1.\",\n      \"method\": \"Co-immunoprecipitation, yeast two-hybrid, overexpression apoptosis assays\",\n      \"journal\": \"The EMBO Journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP with multiple binding partners, Apaf-1 domain mapping, functional disruption assays\",\n      \"pmids\": [\"9878060\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Human BCL2L10 (Bcl2-L-10) blocks the mitochondrial apoptosis pathway (cytochrome c release, caspase-3 activation, mitochondrial membrane potential collapse) induced by IL-3 withdrawal and Bax overexpression, but cannot block TNFα-induced (death receptor) apoptosis. Both the BH4 domain and the transmembrane domain are required for anti-apoptotic function.\",\n      \"method\": \"Transient transfection, flow cytometry for apoptosis and ΔΨm, caspase-3 activation assay, domain deletion mutants\",\n      \"journal\": \"Human Molecular Genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — domain mutagenesis combined with multiple functional readouts in defined pathway contexts\",\n      \"pmids\": [\"11689480\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Bcl-B (human BCL2L10) selectively binds Bax but not Bak, suppresses Bax-induced but not Bak-induced apoptosis, and requires its C-terminal transmembrane domain for association with intracellular organelles and full anti-apoptotic function. It also binds Bcl-2 and Bcl-XL.\",\n      \"method\": \"Co-immunoprecipitation, GST pulldown, transient transfection apoptosis assays, TM-deletion mutants\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple binding assays plus functional mutagenesis, strong mechanistic correlation\",\n      \"pmids\": [\"11278245\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Human Boo/Diva (BCL2L10) promotes cell death in HeLa and 293 cells; GFP-tagged Boo/Diva translocates from a non-mitochondrial localization to mitochondria during vincristine-induced apoptosis. Bcl-XL interacts with Boo but cannot protect cells from Boo/Diva-induced death.\",\n      \"method\": \"GFP live-cell imaging, co-immunoprecipitation, transient transfection cell death assays\",\n      \"journal\": \"Biochimica et Biophysica Acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct localization experiment with functional consequence, single lab\",\n      \"pmids\": [\"11566354\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Genetic inactivation of Diva (BCL2L10) in mice shows that Diva is dispensable for normal ovarian development, fertility, and genotoxic stress-induced apoptosis, indicating functional redundancy with other Bcl-2 family members in vivo.\",\n      \"method\": \"Gene targeting (knockout mouse), histological analysis, apoptosis assays after genotoxic stress\",\n      \"journal\": \"Molecular and Cellular Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic knockout with rigorous phenotypic analysis\",\n      \"pmids\": [\"12215543\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"The differential binding specificity of Bcl-B (BCL2L10) for Bax (but not Bak) is determined by the BH3 domain of Bax: Bcl-B binds chimeric Bak containing Bax's BH3 domain, and Bcl-B BH3-pocket mutants (L86A, R96Q) lose Bax-binding and fail to suppress Bax-induced apoptosis, demonstrating tight structure–function correlation.\",\n      \"method\": \"BH3 chimeric mutants, alanine-scanning mutagenesis, structure-based BH3-pocket mutagenesis, co-immunoprecipitation, cell death assays\",\n      \"journal\": \"The Biochemical Journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — structure-based mutagenesis with reconstitution of binding and functional apoptosis suppression\",\n      \"pmids\": [\"12921534\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Orphan nuclear receptor Nur77/TR3 binds BCL-B (BCL2L10) with the highest affinity among anti-apoptotic Bcl-2 family members and converts its phenotype from anti-apoptotic to pro-apoptotic. Endogenous BCL-B and Nur77 associate in RPMI 8226 myeloma cells, and BCL-B knockdown abolishes Nur77-induced apoptosis.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, overexpression cell death assays, fluorescence polarization binding assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal endogenous Co-IP, siRNA epistasis, multiple orthogonal methods\",\n      \"pmids\": [\"17227826\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"NM23-H2 interacts with Diva (BCL2L10 mouse ortholog) in a transmembrane domain-dependent manner and down-regulates Diva protein levels; NM23-H2 knockdown restores Diva expression and increases Diva-mediated apoptotic activity.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, siRNA knockdown, overexpression apoptosis assays\",\n      \"journal\": \"Biochemical and Biophysical Research Communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single lab, Co-IP plus RNAi functional validation\",\n      \"pmids\": [\"17532299\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"BCL-B (BCL2L10) shows strong preference for binding and suppressing Bax over Bak, as assessed by co-immunoprecipitation, GST pulldown, and fluorescence polarization with BH3 peptides. Mcl-1 shows the reciprocal preference for Bak, distinguishing these two anti-apoptotic proteins from Bcl-2, Bcl-XL, Bcl-w, and Bfl-1.\",\n      \"method\": \"Co-immunoprecipitation, GST pulldown, fluorescence polarization with synthetic BH3 peptides, overexpression apoptosis assays\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — three independent protein interaction methods plus functional apoptosis suppression assays\",\n      \"pmids\": [\"18178565\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"BCL2L10 is the predominant maternally loaded Bcl-2 family transcript in oocytes and early embryos, associates with TCTP and mitochondria with stage-specific redistribution along the pericortical ooplasm, co-localizes with BAX in dying oocytes, and its neutralization accelerates oocyte death.\",\n      \"method\": \"mRNA expression profiling, immunofluorescence, co-localization imaging, antibody neutralization, fractionation\",\n      \"journal\": \"Journal of Molecular Medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — direct localization plus functional consequence via neutralization, single lab\",\n      \"pmids\": [\"19551325\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"BCL2L10 knockdown by siRNA in mouse germinal vesicle oocytes causes metaphase I arrest with spindle and chromosome abnormalities, impairs maturation-promoting factor (MPF) activity, but does not affect MAPK activity, indicating a specific role for BCL2L10 in the MI-to-MII oocyte transition.\",\n      \"method\": \"Microinjection of dsRNA, real-time PCR, Western blot, immunofluorescence, MPF/MAPK activity assays\",\n      \"journal\": \"Biology of Reproduction\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean RNAi knockdown with specific cellular phenotype and pathway dissection\",\n      \"pmids\": [\"19439730\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"HIP1R directly interacts with BCL2L10 (human Diva/BCL-B) in a manner requiring the ANTH and THATCH domains of HIP1R; HIP1R overexpression induces BAK-dependent (but BAX-independent) mitochondrial apoptosis and augments BCL2L10–caspase-9 interaction.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, Far-Western analysis, domain deletion mutants, mitochondrial membrane potential assay, caspase-9 activation\",\n      \"journal\": \"Cellular Physiology and Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct binding confirmed by Far-Western plus domain mapping and functional epistasis\",\n      \"pmids\": [\"19255499\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"BCL2L10 interacts with the BH3 domain of BECN1 (Beclin 1) and suppresses autophagy induced by multiple stimuli; BCL2L10 knockdown triggers BECN1/LC3/ATG5-dependent autophagic cell death, establishing BCL2L10 as a negative regulator of autophagy.\",\n      \"method\": \"Co-immunoprecipitation, overexpression and siRNA knockdown, autophagy flux assays (LC3), flow cytometry, ATG5/BECN1 knockdown epistasis\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP, multiple autophagy readouts, genetic epistasis with autophagic machinery components\",\n      \"pmids\": [\"22498477\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"BCL2L10 overexpression in gastric cancer cells induces apoptosis via the mitochondrial pathway and suppresses tumor growth; BCL2L10 siRNA activates PI3K-Akt signaling to promote proliferation, indicating context-dependent dual roles in gastric cancer cells.\",\n      \"method\": \"Flow cytometry, fluorescence staining, murine xenograft, Western blot, PI3K pathway inhibitors, siRNA\",\n      \"journal\": \"The Journal of Pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional readouts in vitro and in vivo with pathway inhibitor confirmation\",\n      \"pmids\": [\"21171085\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Diva (BCL2L10 mouse ortholog) interacts with Harakiri (HRK, a BH3-only protein) via a surface equivalent to the canonical BH3-binding groove of anti-apoptotic Bcl-2 proteins, as mapped by NMR spectroscopy and molecular docking.\",\n      \"method\": \"ELISA, NMR spectroscopy, molecular docking, circular dichroism\",\n      \"journal\": \"PLoS One\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — NMR-based structural mapping combined with binding affinity measurements\",\n      \"pmids\": [\"21209886\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"BCL2L10 contains two divergent indel regions: an N-terminal extension and a loop between predicted α5-α6 helices. The α5-α6 interhelical region in human BCL2L10 has acquired negatively charged residues consistent with a calcium-binding motif; deletion of the N-terminal extension had no functional impact, while mutations in the α5-α6 loop affected protein behavior.\",\n      \"method\": \"Phylogenetic analysis, truncation and site-directed mutagenesis, biochemical assays, cell biological functional assays\",\n      \"journal\": \"Molecular Biology and Evolution\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mutagenesis with functional validation, single lab\",\n      \"pmids\": [\"21705382\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"BCL2L10 (BCLb) is stabilized by Ubiquilin1 (UBQLN1) at the post-translational level; Ubqln1 promotes monoubiquitination of BCLb on multiple lysine residues and relocalizes it to the cytosol. In the absence of Ubqln1 interaction, BCLb protein is rapidly degraded after protein synthesis inhibition.\",\n      \"method\": \"Immunoaffinity purification, mass spectrometry, cycloheximide chase, co-immunoprecipitation, protein stability assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences USA\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — MS-identified interaction, multiple biochemical validations of stability mechanism\",\n      \"pmids\": [\"22233804\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"BCL-B (BCL2L10) is polyubiquitinated via K48-linked chains at lysine K128 (and potentially K119/K120) within the loop between BH1 and BH2 domains, targeting it for proteasomal degradation. A lysineless BCL-B mutant has fivefold higher protein expression and enhanced anti-apoptotic activity.\",\n      \"method\": \"Mutagenesis, mass spectrometry, linkage-specific polyubiquitin antibodies, proteasome inhibitor assays, Western blot\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mass spectrometry confirmed ubiquitination site, mutagenesis functional validation, replicated by independent Beverly 2012 study\",\n      \"pmids\": [\"23563182\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"BCL-B (BCL2L10) has high-affinity interactions restricted to BH3-only proteins Bim and Bik only (not Bad, Bik alone broadly, PUMA, NOXA, tBid, HRK); crystal structure of BCL-B:Bim complex at 1.9 Å resolution revealed an unstructured loop insertion between helices α5 and α6 distinguishing BCL-B from other Bcl-2 family members.\",\n      \"method\": \"Crystal structure (1.9 Å), fluorescence polarization binding assays, cell-based apoptosis assays\",\n      \"journal\": \"Cell Death & Disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution crystal structure with functional validation by multiple biophysical and cell-based methods\",\n      \"pmids\": [\"23235460\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"BCL-B (BCL2L10) is not targeted by BH3-mimetic ABT-737 (which targets Bcl-2, Bcl-xL, Bcl-w); BCL-B-mediated apoptosis resistance is specifically overcome by BH3-only protein Noxa but not by Bim, PUMA, or truncated Bid, as demonstrated in human T-leukemic cells with inducible expression.\",\n      \"method\": \"Inducible expression, apoptosis assays, ABT-737 drug treatment, BH3-only protein knockin/knockdown\",\n      \"journal\": \"Cell Death & Disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — inducible expression system, multiple BH3-only proteins tested, single lab\",\n      \"pmids\": [\"22875003\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"BCL2L10 knockdown sensitizes AZA-resistant myeloid cells (SKM1-R) to azacitidine-induced cell death, linking elevated BCL2L10 expression to drug resistance in myeloid cells.\",\n      \"method\": \"siRNA knockdown, cell viability assays, flow cytometry\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional RNAi knockdown with specific drug-resistance phenotype, single lab\",\n      \"pmids\": [\"22577154\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"IRBIT interacts with BCL2L10 and they additively inhibit IP3R in physiological conditions. Upon apoptotic stress, IRBIT is dephosphorylated and becomes an inhibitor of BCL2L10. IRBIT and BCL2L10 associate in mitochondria-associated membranes (MAMs), and IRBIT promotes ER–mitochondria contact, facilitating massive Ca2+ transfer and apoptosis.\",\n      \"method\": \"Co-immunoprecipitation, IP3R binding assays, mitochondria-associated membrane fractionation, Ca2+ imaging, apoptosis assays, phosphorylation analysis\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods including fractionation, functional Ca2+ assays, and phosphorylation-dependent mechanistic epistasis\",\n      \"pmids\": [\"27995898\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"BCL2L10 (Nrh) localizes to the endoplasmic reticulum and inhibits IP3R-mediated ER-Ca2+ release through BH4 domain-dependent interaction with the ligand-binding domain of IP3R type 1/3; disruption of Nrh/IP3R complexes by BH4 mimetic peptides inhibits breast cancer cell growth in vitro and in vivo.\",\n      \"method\": \"Co-immunoprecipitation, Ca2+ release assays, subcellular fractionation, domain mutagenesis, BH4 peptide competition, xenograft mouse model\",\n      \"journal\": \"Cancer Research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — BH4 domain mutagenesis, direct IP3R binding assays, peptide disruption with in vivo validation\",\n      \"pmids\": [\"29330143\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"BCL-B (BCL2L10) suppresses mitophagy in hepatic stellate cells by directly binding phosphorylated Parkin (a key mitophagy regulator) and inhibiting its phosphorylation; BCL-B knockdown increases both mitophagy and apoptosis in HSCs during hepatic fibrosis regression.\",\n      \"method\": \"Co-immunoprecipitation, Western blot for phospho-Parkin, BCL-B knockdown and overexpression, mitophagy assays, in vivo mouse fibrosis model\",\n      \"journal\": \"Experimental & Molecular Medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct binding confirmed by Co-IP, functional mitophagy assays, in vivo validation, single lab\",\n      \"pmids\": [\"30635551\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"BCL2L10 inhibits autophagy in hepatoma cells by binding Beclin 1 (BECN1), which reduces the interaction between Beclin 1 and PI3KC3, thereby downregulating PI3K/AKT-dependent autophagy.\",\n      \"method\": \"Co-immunoprecipitation, ELISA, immunofluorescence co-localization, autophagic flux assay (LC3B-II/P62), pathway inhibition\",\n      \"journal\": \"Aging\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple binding assays and functional autophagy readouts, PI3K pathway confirmation, single lab\",\n      \"pmids\": [\"30696802\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"BCL2L10 expression in melanoma is driven by STAT3-mediated transcription; functional STAT3-responsive elements in the BCL2L10 promoter were identified by reporter assays, site-directed mutagenesis, and ChIP analysis. BCL2L10 confers resistance to cisplatin and ABT-737, and its inhibition sensitizes melanoma cells to these agents.\",\n      \"method\": \"Reporter assays, site-directed mutagenesis, ChIP, siRNA knockdown, drug resistance assays, BRAF inhibitor combination\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — promoter mutagenesis plus ChIP, functional drug resistance phenotype, single lab\",\n      \"pmids\": [\"33396645\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"UBQLN4 interacts with and stabilizes BCL2L10 (and BCL2A1) in mesothelioma cells; UBQLN4 is identified as an ATM kinase substrate, and the UBQLN4–BCL2L10 interaction prevents mesothelioma cell apoptosis in response to DNA damage.\",\n      \"method\": \"Genetic screening, co-immunoprecipitation, ATM substrate identification, cell death assays upon DNA damage\",\n      \"journal\": \"Molecular Oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP binding confirmed, ATM substrate identification, functional apoptosis assay, single lab\",\n      \"pmids\": [\"34245648\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"BCL2L10 (also known as Bcl-B, Diva, Boo, Nrh) is an anti-apoptotic Bcl-2 family member that blocks the mitochondrial apoptosis pathway via BH4 domain-dependent inhibition of IP3R-mediated Ca2+ release at the ER (and in MAMs), selective binding and neutralization of pro-apoptotic Bax (but not Bak) through a restricted BH3-binding groove, inhibition of Beclin 1-dependent autophagy, and suppression of Parkin-mediated mitophagy; its protein stability is regulated by K48-linked polyubiquitination at K128 (targeting it for proteasomal degradation) which is antagonized by Ubiquilin1/UBQLN4, its anti-apoptotic phenotype can be converted to pro-apoptotic by Nur77/TR3 binding, and its expression is transcriptionally driven by STAT3.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"BCL2L10 is an anti-apoptotic Bcl-2 family member that guards against mitochondrial apoptosis, autophagy, and mitophagy through distinct molecular interactions. It selectively binds and neutralizes pro-apoptotic Bax (but not Bak) via a restricted BH3-binding groove, with specificity determined by the Bax BH3 domain and key groove residues (L86, R96), and additionally inhibits IP3R-mediated ER Ca²⁺ release through its BH4 domain at ER and mitochondria-associated membranes, thereby suppressing Ca²⁺-driven apoptotic signaling [PMID:11689480, PMID:11278245, PMID:12921534, PMID:29330143, PMID:27995898]. BCL2L10 also negatively regulates Beclin 1-dependent autophagy and Parkin-mediated mitophagy through direct binding of these effectors [PMID:22498477, PMID:30635551]. Its protein stability is controlled by K48-linked polyubiquitination at K128 targeting it for proteasomal degradation, counteracted by stabilizing interactions with Ubiquilin1 and UBQLN4, while the orphan nuclear receptor Nur77 converts BCL2L10 from anti-apoptotic to pro-apoptotic upon binding [PMID:23563182, PMID:22233804, PMID:34245648, PMID:17227826]. Transcription of BCL2L10 is driven by STAT3, and its expression confers chemotherapy resistance in melanoma and myeloid malignancies [PMID:33396645, PMID:22577154].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"The initial identification of Diva/BCL2L10 as a Bcl-2 family member that binds Apaf-1 and promotes apoptosis established that this gene encoded an unexpected direct modulator of the apoptosome scaffold, distinct from typical pro- or anti-apoptotic members.\",\n      \"evidence\": \"Co-IP and overexpression apoptosis assays with BH3 deletion mutants in 293T and other cell lines\",\n      \"pmids\": [\"9829980\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Pro-apoptotic function via Apaf-1 binding was later contradicted by anti-apoptotic data in human systems\", \"Binding specificity for Apaf-1 versus Bcl-2 family members not reconciled across species\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Demonstration that mouse Boo/BCL2L10 forms multimeric complexes with Apaf-1 and caspase-9 that are disrupted by BH3-only proteins Bak and Bik resolved its role as an anti-apoptotic guardian of the apoptosome complex.\",\n      \"evidence\": \"Co-IP, yeast two-hybrid, Apaf-1 domain mapping, and overexpression apoptosis assays\",\n      \"pmids\": [\"9878060\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological stoichiometry of the Boo–Apaf-1–caspase-9 complex not determined\", \"Whether Apaf-1 interaction is the primary anti-apoptotic mechanism in vivo remained unclear\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Three independent studies established that human BCL2L10 is an anti-apoptotic protein that selectively binds Bax but not Bak, blocks the mitochondrial (but not death receptor) apoptosis pathway, and requires both BH4 and transmembrane domains for function, defining its mechanism as distinct from Bcl-2/Bcl-XL.\",\n      \"evidence\": \"Domain deletion mutagenesis, Co-IP, GST pulldown, flow cytometry for apoptosis and ΔΨm, GFP live-cell imaging in multiple cell lines\",\n      \"pmids\": [\"11689480\", \"11278245\", \"11566354\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for Bax selectivity over Bak not yet determined\", \"Translocation from non-mitochondrial sites to mitochondria observed but trigger mechanism unknown\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Genetic knockout of Diva in mice revealed functional redundancy with other Bcl-2 family members, demonstrating that BCL2L10 is dispensable for normal ovarian development and genotoxic apoptosis in vivo.\",\n      \"evidence\": \"Gene targeting (knockout mouse), histological analysis, apoptosis assays after genotoxic stress\",\n      \"pmids\": [\"12215543\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Compensatory mechanisms not identified\", \"Tissue-specific or stress-specific non-redundant roles not tested beyond ovary and genotoxic stress\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Structure–function analysis of the BH3-binding groove revealed that BCL2L10's selectivity for Bax over Bak is determined by the BH3 domain of Bax itself, and specific groove residues (L86, R96) are required for both Bax binding and anti-apoptotic function.\",\n      \"evidence\": \"BH3 chimeric mutants, alanine-scanning and structure-based mutagenesis, Co-IP, cell death assays\",\n      \"pmids\": [\"12921534\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No crystal or NMR structure of BCL-B alone or with Bax at this time\", \"Whether this selectivity operates in endogenous protein contexts not shown\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Discovery that orphan nuclear receptor Nur77/TR3 binds BCL2L10 with highest affinity among anti-apoptotic Bcl-2 proteins and converts it to a pro-apoptotic effector revealed a novel regulatory switch that could override BCL2L10 survival function.\",\n      \"evidence\": \"Reciprocal endogenous Co-IP in myeloma cells, siRNA epistasis, fluorescence polarization binding assays\",\n      \"pmids\": [\"17227826\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural mechanism of phenotypic conversion not determined\", \"Whether Nur77 exposes Bax or disrupts Apaf-1 complexes unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"BCL2L10 was found to be the predominant Bcl-2 family transcript in oocytes, and its knockdown causes metaphase I arrest with impaired MPF activity, establishing a non-apoptotic role in oocyte meiotic maturation.\",\n      \"evidence\": \"dsRNA microinjection in mouse oocytes, immunofluorescence, MPF/MAPK activity assays, antibody neutralization\",\n      \"pmids\": [\"19439730\", \"19551325\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How BCL2L10 regulates MPF activity is mechanistically undefined\", \"Whether this function is Bax-dependent or independent not addressed\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"BCL2L10 was shown to bind the BH3 domain of Beclin 1 and suppress autophagy, with knockdown triggering Beclin 1/LC3/ATG5-dependent autophagic cell death, establishing BCL2L10 as a dual inhibitor of apoptosis and autophagy.\",\n      \"evidence\": \"Reciprocal Co-IP, autophagy flux assays, siRNA knockdown with genetic epistasis using ATG5 and BECN1\",\n      \"pmids\": [\"22498477\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contributions of anti-apoptotic versus anti-autophagic functions in physiological contexts not dissected\", \"Whether autophagy inhibition requires the same BH3 groove as Bax binding unknown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Crystal structure of BCL-B bound to Bim BH3 peptide at 1.9 Å revealed an unstructured loop between helices α5–α6 unique to BCL2L10, and biophysical profiling showed high-affinity binding restricted to Bim and Bik among BH3-only proteins, distinguishing it from all other anti-apoptotic family members.\",\n      \"evidence\": \"X-ray crystallography (1.9 Å), fluorescence polarization with BH3 peptide panel, cell-based apoptosis assays\",\n      \"pmids\": [\"23235460\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure of BCL-B bound to full-length Bax not available\", \"Functional significance of the α5–α6 loop not fully resolved\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identification of K48-linked polyubiquitination at K128 as the primary signal for BCL2L10 proteasomal degradation, and stabilization by Ubiquilin1-mediated monoubiquitination, established the post-translational control circuit governing BCL2L10 protein levels.\",\n      \"evidence\": \"Mass spectrometry, linkage-specific ubiquitin antibodies, lysineless mutant with enhanced anti-apoptotic activity, cycloheximide chase, immunoaffinity purification\",\n      \"pmids\": [\"23563182\", \"22233804\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ligase responsible for K48-linked ubiquitination at K128 not identified\", \"Whether mono- and polyubiquitination compete at the same lysines not resolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"The IRBIT–BCL2L10 interaction at mitochondria-associated membranes (MAMs) revealed a phosphorylation-dependent regulatory switch: under normal conditions both cooperatively inhibit IP3R Ca²⁺ release, but upon apoptotic stress, dephosphorylated IRBIT antagonizes BCL2L10 and promotes ER-to-mitochondria Ca²⁺ transfer to execute apoptosis.\",\n      \"evidence\": \"Co-IP, MAM fractionation, Ca²⁺ imaging, phosphorylation analysis, apoptosis assays\",\n      \"pmids\": [\"27995898\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the phosphatase that dephosphorylates IRBIT under stress not known\", \"Whether this MAM mechanism operates in all cell types not tested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstration that BCL2L10 inhibits IP3R-mediated Ca²⁺ release specifically through its BH4 domain interacting with the ligand-binding domain of IP3R1/3 at the ER, with BH4-mimetic peptides disrupting this interaction and suppressing breast cancer growth in vivo, defined a druggable ER-localized anti-apoptotic mechanism.\",\n      \"evidence\": \"Co-IP, Ca²⁺ release assays, subcellular fractionation, BH4 domain mutagenesis, BH4 peptide competition, xenograft model\",\n      \"pmids\": [\"29330143\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural details of BH4–IP3R interface not resolved at atomic level\", \"Whether BH4 peptides affect other BH4-dependent interactions not assessed\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"BCL2L10 was shown to suppress Parkin-mediated mitophagy by directly binding phosphorylated Parkin and inhibiting its phosphorylation, expanding BCL2L10's protective repertoire to mitochondrial quality control in hepatic stellate cells.\",\n      \"evidence\": \"Co-IP of BCL-B with phospho-Parkin, knockdown and overexpression, mitophagy assays, in vivo mouse fibrosis model\",\n      \"pmids\": [\"30635551\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which BCL2L10 inhibits Parkin phosphorylation (PINK1 competition?) not determined\", \"Single lab finding in hepatic stellate cells; generalizability unclear\", \"Reciprocal validation with endogenous proteins limited\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identification of STAT3 as a direct transcriptional activator of BCL2L10 through functional promoter elements linked BCL2L10 upregulation to oncogenic signaling and chemotherapy resistance in melanoma.\",\n      \"evidence\": \"Promoter reporter assays, site-directed mutagenesis of STAT3 elements, ChIP, siRNA knockdown, drug resistance assays\",\n      \"pmids\": [\"33396645\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether STAT3 drives BCL2L10 in non-melanoma contexts not established\", \"Additional transcription factors regulating BCL2L10 not characterized\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"UBQLN4 was identified as a second Ubiquilin family stabilizer of BCL2L10 and linked to ATM-dependent DNA damage signaling, connecting BCL2L10 protein stability to the DNA damage response in mesothelioma.\",\n      \"evidence\": \"Genetic screening, Co-IP, ATM substrate identification, cell death assays upon DNA damage\",\n      \"pmids\": [\"34245648\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether UBQLN1 and UBQLN4 act redundantly or in different contexts not resolved\", \"How ATM phosphorylation of UBQLN4 modulates BCL2L10 binding not mechanistically defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The E3 ubiquitin ligase targeting BCL2L10 for K48-linked degradation remains unidentified, the structural basis of Nur77-mediated phenotypic conversion is unknown, and how BCL2L10 regulates MPF activity during oocyte meiosis has no mechanistic explanation.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ligase for K48-linked ubiquitination at K128 not identified\", \"No structure of BCL2L10 with full-length Bax or Nur77\", \"Mechanism linking BCL2L10 to MPF regulation in oocytes completely unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [2, 3, 6, 9, 13, 23, 24, 25]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [2, 4, 10, 22]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [22, 23]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [17]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [0, 1, 2, 3, 6, 7, 9, 18, 22, 23]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [13, 25]},\n      {\"term_id\": \"R-HSA-1852241\", \"supporting_discovery_ids\": [24]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"BAX\", \"BECN1\", \"APAF1\", \"ITPR1\", \"NR4A1\", \"UBQLN1\", \"UBQLN4\", \"PRKN\"],\n    \"other_free_text\": []\n  }\n}\n```"}